681 related articles for article (PubMed ID: 19112166)
21. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
[TBL] [Abstract][Full Text] [Related]
22. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.
O'Leary DH; Reuwer AQ; Nissen SE; Després JP; Deanfield JE; Brown MW; Zhou R; Zabbatino SM; Job B; Kastelein JJ; Visseren FL;
Heart; 2011 Jul; 97(14):1143-50. PubMed ID: 21610270
[TBL] [Abstract][Full Text] [Related]
23. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
[TBL] [Abstract][Full Text] [Related]
24. Rimonabant: new data and emerging experience.
Wright SM; Dikkers C; Aronne LJ
Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
[TBL] [Abstract][Full Text] [Related]
25. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Rodés-Cabau J; Cannon CP; Deanfield JE; Després JP; Kastelein JJ; Steinhubl SR; Kapadia S; Yasin M; Ruzyllo W; Gaudin C; Job B; Hu B; Bhatt DL; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1547-60. PubMed ID: 18387931
[TBL] [Abstract][Full Text] [Related]
26. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
Savinova OV; Fillaus K; Harris WS; Shearer GC
Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
[TBL] [Abstract][Full Text] [Related]
27. Rimonabant for overweight or obesity.
Curioni C; André C
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006162. PubMed ID: 17054276
[TBL] [Abstract][Full Text] [Related]
28. Smoking inhibits visceral fat accumulation in Turkish women: relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance, and blood pressure.
Onat A; Ayhan E; Hergenç G; Can G; Barlan MM
Metabolism; 2009 Jul; 58(7):963-70. PubMed ID: 19411085
[TBL] [Abstract][Full Text] [Related]
29. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
[TBL] [Abstract][Full Text] [Related]
30. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296
[TBL] [Abstract][Full Text] [Related]
31. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.
Smith SR; Stenlof KS; Greenway FL; McHutchison J; Schwartz SM; Dev VB; Berk ES; Kapikian R
Obesity (Silver Spring); 2011 Sep; 19(9):1796-803. PubMed ID: 21720429
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
Aronne LJ; Isoldi KK
Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
[TBL] [Abstract][Full Text] [Related]
33. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
34. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
Migrenne S; Lacombe A; Lefèvre AL; Pruniaux MP; Guillot E; Galzin AM; Magnan C
Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R929-35. PubMed ID: 19211723
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
38. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Mohapatra J; Sharma M; Singh S; Pandya G; Chatterjee A; Balaraman R; Patel PR; Jain MR
J Pharm Pharmacol; 2009 Nov; 61(11):1493-8. PubMed ID: 19903374
[TBL] [Abstract][Full Text] [Related]
39. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
40. Rimonabant for the treatment of overweight and obese people.
Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]